Akebia Therapeutics Company Profile (NASDAQ:AKBA)

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $1.00. The company earned $20.87 million during the quarter, compared to analyst estimates of $16.50 million. View Akebia Therapeutics' Earnings History.

6 brokers have issued twelve-month target prices for Akebia Therapeutics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Akebia Therapeutics' share price to reach $19.67 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

• 1. Aegis analysts commented, "Well known brands in the ESA market place include Epogen and Aranesp by Amgen, Procrit and Eprex by J&J, and Mirceraby Roche. Emerging, direct competitors in the HIF-PH class include Akebia’s vadadustat, Fibrogen’s roxadustat, Bayer’s molidustat, and Glaxo Smithkline’s daprodustat. Among the HIP-PH product candidates in development, Fibrogen (FGEN, non-rated) is positioned to obtain regulatory approval first, potentially as early 2019, followed by Akebia’s vadadustat in 2020. In our opinion, Akebia’s potential 18 month lag behind Fibrogen (FGEN, non-rated) could work well for the company as we anticipate a gradual adoption of the HIF-PH class by nephrologists. According to surveys conducted by Decision Resource Group in 2015, most nephrologists – over 60% of those surveyed – do not yet differentiate between the oral HIF-PH inhibitors in development." (3/24/2017)
• 2. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/28/2017)
• 3. Brean Capital analysts commented, "We like Akebia's asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care," analyst Difei Yang wrote in a note.Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug"International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone," (9/29/2016)

Some companies that are related to Akebia Therapeutics include Adaptimmune Therapeutics PLC - (ADAP), Geron (GERN), Progenics Pharmaceuticals (PGNX), Spectrum Pharmaceuticals (SPPI), Intra-Cellular Therapies (ITCI), ImmunoGen (IMGN), Merrimack Pharmaceuticals (MACK), NewLink Genetics Corp (NLNK), PTC Therapeutics (PTCT), Arena Pharmaceuticals (ARNA), Atara Biotherapeutics (ATRA), Myokardia (MYOK), Bellicum Pharmaceuticals (BLCM), NanoString Technologies (NSTG), Celldex Therapeutics (CLDX), Seres Therapeutics (MCRB), Lion Biotechnologies (LBIO) and Otonomy (OTIC).

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (19.40%), First Manhattan Co. (9.32%), Vanguard Group Inc. (7.11%), FMR LLC (5.09%), Morgan Stanley (4.76%) and MARSHALL WACE ASIA Ltd (3.78%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Perceptive Advisors LLC, City Financial Investment Co Ltd, Bank of America Corp DE, JPMorgan Chase & Co., Trexquant Investment LP, Segantii Capital Management Ltd and Highbridge Capital Management LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Akebia Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., First Manhattan Co., Acadian Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., TFS Capital LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Akebia Therapeutics.

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Akebia Therapeutics stock can currently be purchased for approximately $13.85.